{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:58:58Z","timestamp":1792803538066,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jconrel.2024.02.007","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T12:24:54Z","timestamp":1707999894000},"page":"806-820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma."],"prefix":"10.1016","volume":"367","author":[{"given":"Amy","family":"Logan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pie","family":"Huda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Kimpton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zerong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristofer J.","family":"Thurecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"McCarroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Moles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kavallaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.02.007_bb0005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2008.16.6876","article-title":"The international neuroblastoma risk group (INRG) staging system: an INRG task force report","volume":"27","author":"Monclair","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0010","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The international neuroblastoma risk group (INRG) classification system: an INRG task force report","volume":"27","author":"Cohn","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0015","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1038\/nrdp.2016.78","article-title":"Neuroblastoma","volume":"2","author":"Matthay","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jconrel.2024.02.007_bb0020","article-title":"Neuroblastoma","volume":"357","author":"Shohet","year":"2017","journal-title":"Br. Med. J."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101332","article-title":"PLK1 inhibition-based combination therapies for cancer management","volume":"16","author":"Su","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.903016","article-title":"Present and future perspective on PLK1 inhibition in Cancer treatment","volume":"12","author":"Chiappa","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0035","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/1078-0432.CCR-09-1380","article-title":"Targeting polo-like kinase in Cancer therapy","volume":"16","author":"Degenhardt","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0040","doi-asserted-by":"crossref","first-page":"12020","DOI":"10.18632\/oncotarget.2664","article-title":"Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer","volume":"6","author":"McCarroll","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2024.02.007_bb0045","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"12","author":"Kanasty","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.644718","article-title":"Insight into the prospects for RNAi therapy of Cancer","volume":"12","author":"Tian","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0055","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/s41388-022-02241-w","article-title":"Targeted siRNA nanocarrier: a platform technology for cancer treatment","volume":"41","author":"Baumer","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2024.02.007_bb0060","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.biomaterials.2011.09.035","article-title":"EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma","volume":"33","author":"Gao","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.02.007_bb0065","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1073\/pnas.1519273113","article-title":"Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies","volume":"113","author":"Weinstein","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121741","article-title":"A robust post-insertion method for the preparation of targeted siRNA LNPs","volume":"620","author":"Swart","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0075","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41565-017-0043-5","article-title":"A modular platform for targeted RNAi therapeutics","volume":"13","author":"Kedmi","year":"2018","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0080","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/adhm.201600263","article-title":"Overcoming instability of antibody-nanomaterial conjugates: next generation targeted nanomedicines using bispecific antibodies","volume":"5","author":"Howard","year":"2016","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0085","doi-asserted-by":"crossref","first-page":"eabm1262","DOI":"10.1126\/scitranslmed.abm1262","article-title":"Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia","volume":"15","author":"Moles","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0090","first-page":"3639","article-title":"Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition","volume":"23","author":"Yano","year":"2003","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120082","article-title":"EGFR targeting for cancer therapy: pharmacology and immunoconjugates with drugs and nanoparticles","volume":"592","author":"Santos","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0100","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1535-7163.MCT-17-0738","article-title":"Targeted doxorubicin-loaded bacterially derived Nano-cells for the treatment of neuroblastoma","volume":"17","author":"Sagnella","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0105","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.7150\/thno.18136","article-title":"Surface De-PEGylation controls nanoparticle-mediated siRNA delivery in vitro and in vivo","volume":"7","author":"Zhu","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2024.02.007_bb0110","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/pharmaceutics5030498","article-title":"Advances in lipid nanoparticles for siRNA delivery","volume":"5","author":"Tam","year":"2013","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2024.02.007_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.84","article-title":"Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma","volume":"4","author":"Kocak","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0120","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2016.05.059","article-title":"Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA","volume":"235","author":"Chen","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.02.007_bb0125","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/onc.2013.11","article-title":"RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model","volume":"33","author":"Byrne","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2024.02.007_bb0130","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1158\/0008-5472.CAN-04-2131","article-title":"Small interfering RNA\u2013mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals","volume":"65","author":"Guan","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0135","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/jnci\/94.24.1863","article-title":"Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells","volume":"94","author":"Sp\u00e4nkuch-Schmitt","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0140","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/neuonc\/noab207","article-title":"A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy","volume":"24","author":"Wang","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jconrel.2024.02.007_bb0145","doi-asserted-by":"crossref","first-page":"8700","DOI":"10.18632\/oncotarget.3901","article-title":"Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis","volume":"7","author":"Czaplinski","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2024.02.007_bb0150","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0155","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","article-title":"High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model","volume":"6","author":"Richman","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0160","doi-asserted-by":"crossref","first-page":"13739","DOI":"10.1021\/acsnano.0c06033","article-title":"Controlling the biological fate of micellar nanoparticles: balancing stealth and targeting","volume":"14","author":"Sivaram","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2024.02.007_bb0165","doi-asserted-by":"crossref","first-page":"7912","DOI":"10.1039\/D2CC02443H","article-title":"Pre-targeting of polymeric nanomaterials to balance tumour accumulation and clearance","volume":"58","author":"Fletcher","year":"2022","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0170","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201700607","article-title":"Recent advances in the generation of antibody-nanomaterial conjugates","volume":"7","author":"Sivaram","year":"2018","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0175","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1535-7163.MCT-15-0151","article-title":"Selective delivery of PEGylated compounds to tumor cells by anti-PEG hybrid antibodies","volume":"14","author":"Tung","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0180","doi-asserted-by":"crossref","first-page":"9930","DOI":"10.1016\/j.biomaterials.2014.08.032","article-title":"One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles","volume":"35","author":"Kao","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.02.007_bb0185","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0190","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.jconrel.2024.02.007_bb0195","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/onc.2016.220","article-title":"Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA\/ROCK signaling and enhanced transendothelial migration","volume":"36","author":"Fife","year":"2017","journal-title":"Oncogene"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924000944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924000944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:59:00Z","timestamp":1759165140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924000944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":39,"alternative-id":["S0168365924000944"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.02.007","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma.","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}